medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2024, Número 1

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2024; 35 (1)


En busca de una escala de riesgo adecuada para los mexicanos. Las insuficiencias de la escala Globorisk

Meaney A, Martínez-Marroquín MY, Samaniego-Méndez V, Fernández-Barros C, Hidalgo I, Nájera N, Ceballos G, Meaney E

Idioma: Inglés [English version]
Referencias bibliográficas: 54
Paginas: 6-15
Archivo PDF: 242.40 Kb.


RESUMEN

Introducción: las escalas de riesgo son útiles en la prevención primaria de las enfermedades cardiovasculares (CV) para detectar sujetos de alto riesgo. En México se utilizan escalas desarrolladas en poblaciones muy diferentes a la nuestra. Recientemente, se ha propuesto el uso de la herramienta de Globorisk para la población mexicana. Hemos demostrado que el baremo ACC/AHA subestima el riesgo medido con el índice TG/C-HDL y el llamado puntaje Lindavista. Ahora comparamos estos últimos con el riesgo calculado con la herramienta Globorisk, cuyas estimaciones originales se ajustaron a los datos nacionales. Material y métodos: la sumatoria de las anormalidades de los datos de 2,602 sujetos sanos (edad, género, masa corporal, cintura, perfil de lípidos y glucemia) conformaron el puntaje Lindavista. Éste y los valores cuartilares del índice TG/C-HDL se compararon con la estimación del riesgo Globorisk para México. Resultados: el riesgo Lindavista y los valores del cociente TG/C-HDL tienen una muy alta correlación lineal, pero Globorisk subestima gruesamente el riesgo. Conclusión: ningún baremo que no tome en cuenta rasgos y factores muy prevalentes en nuestra población (obesidad abdominal y tríada lipídica) expresa correctamente el riesgo. En espera de desarrollar nuestro propio baremo que tome en cuenta los rasgos antropométricos y cardiometabólicos de la población mexicana, se propone al índice TG/C-HDL como una herramienta útil, económica y práctica para la estimación del riesgo de nuestra población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lloyd-Jones DM. Cardiovascular risk prediction. Basic concepts, current status, and future directions. Circulation. 2010; 121: 1768-1777. doi: 10.1161/CIRCULATIONAHA.109.849166.

  2. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97: 1837-1847. doi: 10.1161/01.cir.97.18.1837.

  3. WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019; 7: e1332-e1345. doi: 10.1016/S2214-109X(19)30318-3.

  4. D'Agostino RB, Grundy SM, Sullivan LM, Wilson P, for the CHD Risk Prediction Group. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA. 2001; 286: 180-187. doi: 10.1001/jama.286.2.180.

  5. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987-1003. doi: 10.1016/s0195-668x(03)00114-3.

  6. Ueda P, Woodward M, Lu Y, Hajifathalian K, Al-Wotayan R, Aguilar-Salinas CA et al. Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys. Lancet Diabetes Endocrinol. 2017; 5: 196. Available in: https://doi.org/10.1016/S2213-8587(17)30015-3

  7. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al. Expert Work Group Members. 2013 ACC/AHA Guideline on the assessment of cardiovascular risk. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129 [Suppl 2]: S49-S73. doi: 10.1161/01.cir.0000437741.48606.98.

  8. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42: 2439-2454. Available in: https://doi.org/10.1093/eurheartj/ehab309

  9. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42: 2455-2467. Available in: https://doi.org/10.1093/eurheartj/ehab312

  10. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015; 3: 339-355. doi: 10.1016/S2213-8587(15)00081-9.

  11. Meaney E, Lara-Esqueda A, Ceballos-Reyes GM, Asbun J, Vela A, Martínez-Marroquín Y et al. Cardiovascular risk factors in the urban Mexican population: the FRIMEX study. Publ Health. 2007; 121: 378-384. doi: 10.1016/j.puhe.2006.11.008.

  12. Fanghanel-Salmón G, Gutiérrez-Salmeán G, Samaniego V, Meaney A, Sánchez-Reyes L, Navarrete U et al. Obesity phenotypes in urban middle-class cohorts; the PRIT-Lindavista merging evidence in Mexico: the OPUS PRIME study. Nutr Hosp. 2015; 32: 182-188. doi: 10.3305/nh.2015.32.1.8646.

  13. Meaney A, Ceballos-Reyes G, Gutiérrez-Salmean G, Samaniego-Méndez V, Vela-Huerta A, Alcocer L et al. Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista Study. Baseline data. Arch Cardiol Mex. 2013; 83: 249-256. doi: 10.1016/j.acmx.2013.05.002.

  14. Palloni A, Beltrán-Sánchez H, Pinto G, Wong R. Adult obesity, disease and longevity in Mexico. Salud Publica Mex. 2015; 57 Suppl 1(01): S22-S30. doi: 10.21149/spm.v57s1.7586.

  15. Pavía-López AA, Alcocer-Gamba MA, Ruiz-Gastelum ED, Mayorga-Butrón JL, Mehta R, Díaz-Aragón FA et al. Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica. Arch Cardiol Mex. 2022; 92 (Supl): 1-62. doi: 10.24875/ACM.M22000081.

  16. Martínez-Marroquín Y, Meaney A, Samaniego-Méndez V, Nájera N, Ceballos G, Fernández-Barros C et al. The TG/HDL-c Lipid Ratio as a cardiovascular risk marker in a Mexican urban middle-class population: Do we need a risk score tailored for Mexicans? J Clin Med. 2023; 12 (18): 6005. doi: 10.3390/jcm12186005.

  17. Dixon JR. Guidelines on good clinical practice. Int Digest Health Legis. 1999; 6: 65-74. doi: 10.1080/105294199277860.

  18. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310: 2191-2194. doi: 10.1001/jama.2013.281053.

  19. Diario de la Federación. [(accessed on November 12 2023)]. Available in: http://www.salud.gob.mx/cnts/pdfs/LEY_GENERAL_DE_SALUD.pdf

  20. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN et al. Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: a statement for professionals from the Sub-committee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation. 2005; 111: 697-716. doi: 10.1161/01.CIR.0000154900.76284.F6.

  21. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of12 the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502. doi: 10.1093/clinchem/18.6.499.

  22. Bjornsen K, Aven T. Risk aggregation: what does it really mean? Reliab Eng Syst Saf. 2019; 191: 106524. https://doi.org/10.1016/j.ress.2019.10652.

  23. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997; 96: 2520-2525. doi: 10.1161/01.CIR.96.8.2520.

  24. Barua L, Banik PC, Shariful Islam SM, Faruque M. Application of country-specific Globorisk score to estimate next 10 years risk of cardiovascular diseases and its associated predictors among postmenopausal rural women of Bangladesh: a cross-sectional study in a primary care setting. Lifestyle Med. 2021; 2: e32. Available in: https://doi.org/10.1002/lim2.32

  25. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952. doi: 10.1016/S0140-6736(04)17018-9.

  26. Lanas F, Avezum A, Bautista LE, Diaz R, Luna M, Islam S et al. Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. Circulation. 2007; 115: 1067-1074. doi: 10.1161/CIRCULATIONAHA.106.633552.

  27. Ciruzzi M, Schargrodsky H, Pramparo P, Rivas Estany E, Rodriguez Naude L, De la Noval Garcia R et al. Attributable risks for acute myocardial infarction in four countries of Latin America. Medicina. (Buenos Aires). 2003; 63: 697-703.

  28. Cohorts Consortium of Latin America and the Caribbean (CC-LAC). Derivation, internal validation, and recalibration of a cardiovascular risk score for Latin America and the Caribbean (Globorisk-LAC): A pooled analysis of cohort studies. The Lancet Regional Health – Americas. 2022;9: 100258. https://doi.org/10.1016/j. lana.2022.100258.

  29. Cohorts Consortium of Latin America and the Caribbean (CC-LAC). Derivation, internal validation, and recalibration of a cardiovascular risk score for Latin America and the Caribbean (Globorisk-LAC): a pooled analysis of cohort studies. Lancet Reg Health Am. 2022; 9: 100258. Available in: https://doi.org/10.1016/j.lana.2022.100258

  30. Lajous M, Ortiz-Panoso E, Monge A, Santoyo-Vistrain R, García-Anaya A, Yunes-Díaz E et al. Cohort profile: the Mexican teachers' cohort (MTC). Int J Epidemiol. 2017; 46 (2): e10. doi: 10.1093/ije/dyv123.

  31. Aguilar M, Muñoz-Aguirre P, Cortés-Valencia A, Flores-Torres MH, Catzin-Kuhlmann A, López-Ridaura R et al. Sun exposure and intima-media thickness in the mexican teachers' cohort study. J Womens Health (Larchmt). 2023; 32: 366-374. doi: 10.1089/jwh.2022.0135.

  32. Denova-Gutiérrez E, Flores YN, Gallegos-Carrillo K, Ramírez-Palacios P, Rivera-Paredez B, Muñoz-Aguirre P et al. Health workers cohort study: methods and study design. Salud Publica Mex. 2016; 58: 708-716. Available in: http://dx.doi.org/10.21149/spm.v58i6.8299.

  33. Morales LS, Flores YN, Leng M, Sportiche N, Gallegos-Carrillo K, Salmerón J. Risk factors for cardiovascular disease among Mexican-American adults in the United States and Mexico: a comparative study. Salud Publica Mex. 2014; 56: 197-205. doi: 10.21149/spm.v56i2.7335.

  34. Bernal-Reyes R, Icaza-Chávez ME, Chi-Cervera LA, Remes-Trocheb JM, Amieva-Balmori M, Priego-Parra BA et al. Prevalence and clinical-epidemiologic characteristics of a Mexican population with metabolic (dysfunction) associated fatty liver disease: an open population study. Rev Gastroenterol Mex. 2023; 88: 199-207.

  35. Rojas-Martínez R, Aguilar-Salinas CA, Romero-Martínez M, Castro-Porras L, Gómez-Velasco D, Mehta R. Trends in the prevalence of metabolic syndrome and its components in Mexican adults, 2006-2018. Salud Publica Mex. 2021; 63: 713-724. doi: 10.21149/12835.

  36. Sohail M, Palma-Martínez MJ, Chong AY, Quinto-Cortés CD, Barberena-Jonas C, Medina-Muñoz SG et al. Mexican Biobank advances population and medical genomics of diverse ancestries. Nature. 2023; 622: 775-783. doi: 10.1038/s41586-023-06560-0.

  37. García-Ortiz H, Barajas-Olmos F, Contreras-Cubas C, Córdova EJ, Centeno-Cruz F, Mendoza-Caamal EA et al. The genomic landscape of Mexican Indigenous populations brings insights into the peopling of the Americas. Nat Commun. 2021; 12: 5942. Available in: https://doi.org/10.1038/s41467-021-26188-w

  38. Murguía-Romero M, Jiménez-Flores JR, Sigrist-Flores SC, Espinoza-Camacho MA, Jiménez-Morales M, Piña E et al. Plasma triglyceride/HDL-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J Lipid Res. 2013; 54: 2795-2279. doi: 10.1194/jlr.M040584.

  39. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen male study. Arterioscler Thromb Vasc Biol. 1997; 17: 1114-1120. doi: 10.1161/01.atv.17.6.1114.

  40. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E et al. The triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics (Basel). 2023; 13: 929. doi: 10.3390/diagnostics13050929.

  41. Yokoyama K, Tani S, Matsuo R, Matsumoto N. Increased triglyceride/high-density lipoprotein cholesterol ratio may be associated with reduction in the low-density lipoprotein particle size: assessment of atherosclerotic cardiovascular disease risk. Heart Vessel. 2019; 34: 227-236. doi: 10. 1007/s00380-018-1247-9.

  42. Gutiérrez-Solis AL, Datta Banik S, Méndez-González RM. Prevalence of metabolic syndrome in Mexico: A systematic review and meta-analysis. Metab Syndr Relat Disord. 2018; 16: 395-405. doi: 10.1089/met.2017.0157.

  43. Das Pradhan A, Glynn RJ, Fruchart J-C, MacFadyen JG, Zaharris ES, Everett BM et al. Triglyceride lowering with Pemafibrate to reduce cardiovascular risk. N Engl J Med. 2022; 387: 1923-1934. doi: 10.1056/NEJMoa2210645.

  44. Rubins HB, Rubins SJ, Collins D, Fye CL, Anderson JW, Elam MB et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999; 341: 410-418. doi: 10.1056/NEJM199908053410604.

  45. Tenenbaum A, Fisman EZ. "If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol. 2010; 9: 24. doi: 10.1186/1475-2840-9-24.

  46. Essilfie G, Shavelle DM, Tun H, Platt K, Kobayashi R, Mehra A et al. Association of elevated triglycerides and acute myocardial infarction in young Hispanics. CRM. 2016; 17: 510-514. Available in: http://dx.doi.org/10.1016/j.carrev.2016.06.001

  47. Arca M, Colivicci F, D'Erasmo L, Borghi C, Veronesi C et al. Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL Retrospective Cohort Analysis. J Am Heart Assoc. 2020; 9: e015801. doi: 10.1161/JAHA.119.015801.

  48. Saadatagah S, Pasha AK, Alhalabi L, Sandhyavenu H, Farwati M, Smith CY et al. Coronary heart disease risk associated with primary isolated hypertriglyceridemia; a population?based study. J Am Heart Assoc. 2021; 10: e019343. doi: 10.1161/JAHA.120.019343.

  49. Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: an update. Arch Cardiovasc Dis. 2021; 114: 132-139. Available in: https://doi.org/10.1016/j.acvd.2020.11.006.

  50. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S et al. Triglycerides and the risk of coronary heart disease. 10 158 incident cases among 262 525 participants in 29 western prospective studies. Circulation. 2007; 115: 450-458. https://doi.org/10.1161/CIRCULATIONAHA.106.637793

  51. Aberra T, Peterson ED, Pagidipati NJ, Mulder H, Wojdyla DM, Philip S et al. The association between triglycerides and incident cardiovascular disease: what Is "optimal"? J Clin Lipidol. 2020; 14: 438-447.e3. doi: 10.1016/j.jacl.2020.04.009.

  52. Vallejo-Vaz AJ, Corral P, Schreier L, Raya KK. Triglycerides and residual risk. Curr Opin Endocrinol Diabetes Obes. 2020; 27: 95-103. doi: 10.1097/MED.0000000000000530.

  53. Ye X, Kong W, Zafar MI, Chen L-L. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019; 18: 48. Available in: https://doi.org/10.1186/s12933-019-0851-z

  54. Estrada-García T, Meaney A, López-Hernández D, Meaney E, Sánchez-Hernández O, Rodríguez-Arellano E et al. Hypertension and lipid triad are the most important attributable risks for myocardial infarction in a middle-class urban Mexican population. Ann Nutr Metab 2013; 63 (Suppl 1): 1343 (abstract).




2020     |     www.medigraphic.com